Keywords
drugs in the pharmaceutical ser vice specialized component
organization and administration
patient ser vice management
How to Cite
Abstract
Low prevalence diseases require management models different from those used in other conditions. is work was intended to gather international experiences on this issue. Searches were made in many indexed literature databases as well as in those with gray literature. A panel of experts from different disciplines checked the abstracts and their potential adaptation into the Colombian context. The initial search retrieved 5604 references and the manual search added other 31 references. At the end, 78 articles provided useful information for the analysis. The results allow to state that a management model consists of
several components, to wit: policies, legislation and administrative aspects; definition and coding of the diseases; research and education; specialized centers; excellence centers and service networks; diagnosis, screening , prevention, and promotion; orphan drug inclusion; rehabilitation and palliative care; organizations of patients and support groups or networks; and social-sanitary support (labor and educational inclusion).
90(6):406-7.
2. Montserrat A, Waligóra J. The European Union policy in the eld of rare diseases. Public Health Genomics.
2013;16(6): 268-77.
3. Schieppati A, Henter J, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet.
2008; 371(9629):2039-41.
4. Federación Colombiana de Enfermedades Raras. Una nueva esperanza para las víctimas de enfermedades raras en Colombia [internet] [acceso: 7 de julio de 2015]. Disponible en: http://www.fecoer.org/una-nueva-esperanzapara-las-victimas-de-enfermedades-raras-en-colombia/
5. Sistema Integrado de Información de la Protección Social (Sispro) [internet] [acceso: 16 de octubre de 2015].
Disponible en: http://www.sispro.gov.co
6. Taruscio D, Trama A, Stefanov R. Tackling rare diseases at European level: why do we need a harmonized framework? Folia Med. 2007; 49(1-2):59-67.
7. Forman J, Taruscio D, Llera V. The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 2012; 101(8):805-7.
8. International Conference on Rare Diseases & Orphan Drugs. The Yukiwariso Declaration. 7th International
Conference on Rare Diseases & Orphan Drugs, Tokyo, 2012.
9. Reforma del Sistema General de Seguridad Social en Salud. Ley 1438 de enero 19 de 2011. Diario ocial 47957 de enero 19 de 2011.
10. Toumi M, Pashos C, Korchagina D, Redekop K, Morel T, Blanchette C, et al. Challenges in assessing and appraising rare disease diagnostics & treatments. International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group; 2015.
11. Martínez Carmona MR. Las enfermedades raras y los vacíos jurídicos en la aplicabilidad de la legislación colombiana para su tratamiento [tesis de grado]. Manizales: Facultad de Ciencias Jurídicas, Universidad de Manizales; 2013.
12 . Fretheim A, Schünemann HJ, Oxman AD. Improving the use of research evidence in guideline development: 3. Gro up composition and consultation process. Health Res Policy Syst. 2006; (4).
13. Instituto de Evaluación Tecnológica en Salud. Manual metodológico para la elaboración de evaluaciones de
efectividad, seguridad y validez diagnóstica de tecnologías en salud. Bogotá: Instituto de Evaluación Tecnológica
en Salud - IETS; 2014.
14. Boyd EA, Bero LA. Improving the use of research evidence in guideline development: 4. Managing conicts of interests. Health Res Policy Syst. 2006; (4).
15. Centro de Estudios e Investigación en Salud (CEIS). Guía metodológica para la elaboración de guías de práctica clínica con evaluación económica en el sistema general de seguridad social en salud colombiano: versión completa final. Bogotá: Fundación Santa Fe de Bogotá - Centro de Estudios e Investigación en Salud; 2014.
16. Fretheim A, Schünemann HJ, Oxman AD. Improving the use of research evidence in guideline development: 5.
Group processes. Health Res Policy Syst. 2006; (4).
17. Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC. How to write a Cochrane systematic review.
Nephrolog y. 2010; 15(6):617-24.
18. National Institute for Health and Care Excellence. The guidelines manual. Londres: National Institute for Health a nd Care Excellence; 2012.
19. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA., Alonso-Coello P, et al. GRADE guidelines: 9. Rating up
the quality of evidence. J Clin Epidemiol. 2011; 64(12):1311-6.
Copyright notice
The Journal Management and Health Policies is registered under the Creative Commons Recognition 4.0 International license. Therefore, this work can be reproduced, distributed and publicly communicated in digital format, provided that the name of the authors and the Pontificia Universidad Javeriana are recognized. It is allowed to quote, adapt, transform, autoarchive, republish and create from the material, for any purpose (including commercial), provided that authorship is properly acknowledged, a link to the original work is provided and if changes have been mad. The Pontificia Universidad Javeriana does not retain the rights over published works and the contents are the exclusive responsibility of the authors, who preserve their moral, intellectual, privacy and publicity rights.
The endorsement of the intervention of the work (revision, style correction, translation, layout) and its subsequent disclosure is granted through a license to use and not through a transfer of rights, which means that the journal and the Pontificia Universidad Javeriana disclaims any liability that may arise from ethical misconduct on the part of the authors. As a result of the protection provided by the license for use, the journal is not obliged to publish retractions or modify the information already published, unless the erratum arises from the process of editorial management. The publication of contents in this magazine does not represent royalties for taxpayers.